Ausun Pharm(SH:603229)2023-10-27 16:00Financial Performance - The company's revenue for Q3 2023 was CNY 202,946,435.18, representing a year-over-year increase of 3.25%[4] - Net profit attributable to shareholders for Q3 2023 was CNY 65,140,884.49, up 20.51% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses for Q3 2023 was CNY 59,212,971.21, reflecting a 23.58% increase year-over-year[4] - Basic earnings per share for Q3 2023 was CNY 0.11, an increase of 22.22% year-over-year[4] - Total operating revenue for the first three quarters of 2023 reached ¥671,662,047.60, an increase of 16.2% compared to ¥577,913,726.42 in the same period of 2022[16] - Net profit for the first three quarters of 2023 was ¥225,337,632.82, representing a 27.2% increase from ¥177,077,646.30 in the previous year[17] - Earnings per share for the first three quarters of 2023 were ¥0.38, compared to ¥0.31 in the same period of 2022, indicating a growth of 22.6%[17] Cash Flow - The net cash flow from operating activities for Q3 2023 was negative CNY 30,176,859.84, a decrease of 134.45% compared to the previous year[4] - The net cash inflow from operating activities for Q3 2023 was CNY 10,286,467.01, a decrease of 90.9% compared to CNY 112,871,999.25 in Q3 2022[20] - The total cash inflow from operating activities was CNY 708,900,804.99, compared to CNY 655,754,734.60 in Q3 2022, reflecting a growth of 8.3%[20] - The total cash outflow from operating activities was CNY 698,614,337.98, an increase of 28.7% from CNY 542,882,735.35 in the previous year[20] - The company received tax refunds amounting to CNY 37,382,108.55, compared to CNY 24,846,283.94 in Q3 2022, indicating a growth of 50.2%[20] - The company reported a cash increase of CNY 388,052,554.78 for the quarter, compared to CNY 42,301,943.10 in Q3 2022, marking a significant improvement[21] Assets and Liabilities - Total assets at the end of Q3 2023 amounted to CNY 2,973,290,511.32, a 28.42% increase from the end of the previous year[5] - Shareholders' equity attributable to the parent company reached CNY 2,113,049,904.50, up 44.62% compared to the end of the previous year[5] - The total liabilities as of the end of the third quarter of 2023 were ¥860,240,606.82, slightly up from ¥854,189,668.14 in the previous year[16] - The company's total current liabilities increased to RMB 1,000,000,000, with short-term borrowings rising to RMB 250,279,855.18 from RMB 160,120,228.06, a growth of approximately 56.4%[12] - Non-current assets totaled RMB 1,260,158,649.11, up from RMB 1,178,625,030.82, indicating an increase of about 6.9%[12] Investments and Expenses - Research and development expenses for the first three quarters of 2023 totaled ¥73,686,399.20, up from ¥52,596,549.73 in the same period of 2022, marking a significant increase of 40%[16] - Total operating costs for the first three quarters of 2023 were ¥419,225,427.62, up from ¥382,244,257.88 in 2022, reflecting a rise of 9.7%[16] Other Financial Metrics - The weighted average return on net assets for Q3 2023 was 3.02%, a decrease of 0.91 percentage points from the previous year[5] - Non-recurring gains and losses for Q3 2023 totaled CNY 5,927,913.28, with a year-to-date total of CNY 12,892,197.50[7] - The company reported a financial income of ¥22,091,667.01 for the first three quarters of 2023, compared to ¥4,397,074.29 in the same period of 2022, showing a substantial increase[16] - Deferred income tax liabilities increased to ¥13,018,281.46 from ¥12,514,059.91 year-over-year, reflecting a growth of 4%[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 32,617[9]